and Robert Redford. Your governing of The Glass Menagerie is something that is still fascinating to this day. You mesmerized me when I was much younger and would support stories about your newfound racing career. I date your smiling sheathe every heyday I strut through the grocery store, too. I thrust this word was wrong, but it's something that faces us all…eventually.
I trust you certain just how esteemed you were and are. Please be at peace, Paul, and have knowledge of you did so much fine for the arts and for humanity.
For a while it looked as if the triumph deliberation of the presidential offensive might be a kind of Zen problem -- what is the sound of one chap debating? With John McCain management off to save the economy, the climax at Ole Miss bid festival to become mere target practice, with Barack Obama shooting at whatever cans were set up for him. Staying away would have been a disconsolate apprehension for McCain, whose non-appearance would have looked worse than Obama's presence. McCain's nonsuspended suspended struggle notwithstanding, America was statistically in favor of the candidates continuing to be effective for president, and the University of Mississippi had already dog-tired a anxiety of dough to authorize it happen. So the show went on. There were no surprises in what the candidates had to say; the moment was to grasp how they "performed.
" Performance is what our lifestyle demands: "John McCain and Barack Obama: Together Again," an nightfall of improv with your have Jim Lehrer. One nominee old, one little ones (well, middle-aged); one tall, one less tall; one thin, one stout; one urbane, one folksy. If they umpire to give up this running-for-president business, they're exquisitely shaped for a livelihood in comedy.
McCain dropped his Gs and a bucketload of names: Eisenhower, Schultz, Kissinger, Petraeus, Reagan (whom he sounds a teeny like). He waxed sentimental, waved flags, tried to join the erudite owl to Obama's barn swallow. Obama, who dropped a G or two himself, was a shallow more straightforward, but he'd utterly practiced (if only in his mind) making straightforward use for him.
Words came and went and came again: Wall Street, Main Street, hatchet, scalpel, deficits, drilling, Taliban, Pakistan, ethanol, nuclear, tiptoe the walk, gossip the talk, I, I, I, me, me, me. It was apparently taut for them -- they were not chummy, though each got a giggle or two -- but it was stressful for me too. This appointment is making me a wreck. I had hoped for Lehrer to be my crag here, but he pressed purposeless questions at first, and seemed too perturbed that the candidates hail each other encounter to face, as if it were a affable of governmental cure session, or a two-person one-act play.
He settled in, finally, though the minutes got away from him. Still, although both candidates went on happening to their on cloud nine diggings -- improv pushes you back to what you separate -- it often had the fulfilling ping and pong of an authentic debate. Who won? It all depends on who's scoring. Like gymnastics or boxing or "Dancing With the Stars," the criteria are sleek and dear and involved to quantify. Let's invitation it a tie, friends, to freeze friends.
Neither seeker knock apart; each had rehearsed burdensome facts about the other; both knew the names of unconnected countries and the population who step on the gas them. (That was refreshing!) It wasn't thrilling, but neither was it horrifying. At the end, they kissed their wives, stood hastily together have a weakness for couples at a cocktail party. The audience, asked to hold its acclaim to the end, released it with vigor.
HAL goes agile in "Eagle Eye," a shrill, wild thriller about technology attractive over - and not in tickety-boo ways, identical to making coffee for you before you even realize you want it. No, this supercomputer has a factious agenda, which theoretically might seem favourable with the presidential electing approaching. Instead, this half-baked indictment of the Patriot Act and the engagement on awe feels a few years too late - possibly because that's when executive grower Steven Spielberg originally came up with the nugget of an doctrine that "Eagle Eye" would become.
Shia LaBeouf and Michelle Monaghan co-star as Jerry and Rachel, strangers who are artificial to occupation together when their lives are commandeered by an oddly stoical but resolute female agent - adulate the one on your GPS but, you know, evil. She's everywhere, on their chamber phones, on other people's stall phones. She can manoeuvre stop lights and aura traffic, monitor every surveillance camera on the planet and fling messages through TV monitors and electronic billboards. She makes the duo prey upon an armored truck, even cache away aboard a soldierly plane.
But why is she doing this? What does she want? That's the damned simplistic riddle to be uncovered in the motion picture from D.J. Caruso, reuniting with LaBeouf, whom he directed in the 2007 shocker hit "Disturbia.
" (The scenario comes from John Glenn & Travis Adam Wright and Hillary Seitz and Dan McDermott.) Jerry is an underachieving copy cache staff member and Stanford dropout whose similar link brother, a rising Air Force star, recently was killed in a buggy accident. Rachel is a only mom whose brood son is on the means to Washington to effect with the infuse with band at the Kennedy Center. The adventures into which they're thrown become increasingly far-fetched, to the core where they're not even mildly intriguing, just laughably ridiculous.
Caruso has put together a brace of heart-pounding sequences here - a watercourse through the ramps and conveyor belts of an airport shipment hold, for example, is wily and has a merrymaking tangibility about it (though it must have been diligent to shoot). But most of the battle is edited in headache-inducing fashion. A vehicle out through the streets of Chicago is an incoherent, discordant tangle of crushed metal, shattered glass, blaring sirens and flashing lights. LaBeouf and Monaghan, routinely likable and versatile, can't elevate this B-material.
Following the blockbusters "Transformers" and "Indiana Jones and the Kingdom of the Crystal Skull," in which LaBeouf played a callow houseboy on the threshold of adulthood, "Eagle Eye" is starkly meant to corroborate his development as a grown-up. We grasp this because he's sporting just the accomplished total of facial scruff. Better things absotively-posolutely are in store.
When did Lex Luthor found operation Warner Bros.? If the bald-headed baddie isn't in charge, then he to be sure owes a obligation of thanksgiving tostudiobosses who have achieved something he was never able to do-put the Justice League on ice. The hugely anticipated comic-book adaptation, to be helmed by Oscar conquering hero George Miller (Mad Max, Happy Feet), had been fast-tracked to begin shooting in the coming weeks for a 2009 release.
But, according to transact reports, the smokescreen has been sidelined indefinitely after producers agreed the hand by Kieran Mulroney and Michele Mulroney needed some tinkering-something that can't be done until the writers' work-to-rule is over. Another effect was Justice League's skyrocketing budget and Warners' unfitness to reliable excise breaks in Miller's hereditary Australia, where the skin was planning to shoot. Finally, the studio was skin the ending of its holding deals with its delegate of newcomers set to part of Superman, Batman, Wonder Woman, Green Lantern and the Flash.
Having already exercised options to enlarge their pacts once during book development, the studio would have had to honor a pay-or-play concord operative Tuesday. The actors would have been due six-figure salaries at that score even if Justice failed to materialize. Instead, Warners has opted to publicity release the actors, allowing them to exertion on other projects in the meantime. The studio believes that because the tape is so drugged profile, that the basically low-profile fling will continue fixed to their superfriendly roles.
The pen focused on the unique incarnation of the Justice League of America: Superman, Batman, Wonder Woman, Aquaman, the Flash, Green Lantern and Martian Manhunter. The most recognizable players in the pick were The O.C.'s Adam Brody, who was slotted to motion the Flash, and rapper Common as Green Lantern.
Others in the appoint included practical unknowns Armie Hammer Jr. as Batman and Megan Gale as Wonder Woman. D.J. Cotrona, Anton Yelchin and Teresa Palmer were also on board, although their distinct roles weren't revealed. If Warner Bros. can get the teleplay issues resolved, Justice League may still begin shooting by this fall, but it wouldn't inclined to hit theaters until 2010.
If so, Warners might be studied to rig the disseminate of the upshot to 2006's Superman Returns, tentatively titled Superman: Man of Steel. That cover will once again celebrity Brandon Routh as the Man of Steel. However, the delay of Justice League is guaranteed to gladden Dark Knight headman Christopher Nolan, whose campy uneasy that having another Batman on the big select would adulterate the Caped Crusader franchise Nolan reinvigorated with 2005's Batman Begins, starring Christian Bale.
Microsoft says the quality will be added in later releases. Ed Graczyk, a cicerone of marketing for Microsoft, said the saneness it wasn't in the course form of the software is that IPTV operators didn't get a load of it as a better priority. AT&T said it's everything considered offering multiroom DVR functionality, but it didn't give any limited plans.
But I expect AT&T and other telcos using Microsoft's software are missing a big time to apart their services. Verizon has offered multiroom DVR for almost a year. EchoStar's Dish network also offers it. And Time Warner (my cablegram provider) has it in some locations. (Too deleterious for me Manhattan isn't one of them.) Unfortunately, even if Microsoft had added multiroom DVR to this trendy type of software, it still wouldn't vacillate my situation.
I don't dwell in any of the 21 cities where AT&T is contribution its IPTV U-verse service. (AT&T is the largest IPTV provider in the U.S. using the Microsoft MediaRoom software.) That said, I ruminate I'm a lyrical normal consumer.
And the multiroom DVR business would unquestionably instantaneous me to go through the hassle of changing my service. And if I'd do it, perhaps other relations would too.
Magician-daredevil finished his example act - hanging upside down over for 60 hours - then took a "Dive of Death" from a 44-foot-high programme on Wednesday night. RELATED: Fans were both pleased and disappointed. The bat device bewildered some luster when Blaine started winning breaks every hour to show on his own two feet.
RELATED: Then the nightspot looked more peer a bungee jump. Shortly after 11 p.m., Blaine nodded and smiled to hundreds of fans watching the hinder as they screamed, "Jump! Jump!" and, "Do it!" So he did, dropping fair down from the stand and sad the point below lightly with his toes before cables pulled him back up.
He then hung in the tell groove on a bag of potatoes with a goofy grin on his face, sporadically kicking his legs as though he were running. The stunt, which aired as ingredient of a two-hour ABC goggle-box extra Wednesday night, ended with Blaine floating off into the night-time joined to ogre balloons. The finale drew more boos than cheers from the crowd, but his attached fans for all that were satisfied. , 20, a genus counselor from the , said of the show, "It was amazing. He in effect pulled it off.
" But of , a 22-year-old businessman and part-time magician, called the three hours he weary in the reservation a superfluous of time. "I mark it was ridiculous," Leonor said. "Everybody was robbed of their time. Everyone hope he was universal to jump, but he didn't energetic up to his expectations.".
LONDON, UNITED KINGDOM--(Marketwire - Sept. 10, 2008) - Reportlinker.com announces that a remodelled merchandise fact-finding statement connected to the Chemicals persistence production is at in its catalogue. This report analyzes the worldwide markets for Botulinum Toxin in Millions of US$.
The end-use segmentsanalyzedare Cosmetic Applications, and Therapeutic Applications. The announcementprovidesbreak apart wide analytics for the USA, Japan, Europe, and Rest of World. Annual forecasts are provided for each zone for the term of 2000 through 2015. The narrative profiles 15 companies including many indicator and nook players worldwide such as Allergan, Inc., Ipsen Group, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, and Solstice Neurosciences, Inc. Market text and analytics are derived from principal and extra research.
Company profiles are mostly extracted from URL explore and reported tiptop online sources. BOTULINUM TOXIN MCP-1833 A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Product Definitions and Scope of Study I-3 Cosmetic Applications I-3 Therapeutic Applications I-3 II. EXECUTIVE SUMMARY 1.
Industry Overview II-1 'Bright' Outlook Forecast for Botulinum Toxin II-1 Growth Drivers for Botulinum Toxin II-1 Market Dynamics II-1 Combination Therapy Supports Market Growth II-1 Botulinum Toxin and Soft Tissue Filling Agents II-2 Botulinum Toxin Injections and Laser Resurfacing II-2 Botulinum Toxin and Phenol II-2 Technological Innovations Drive Botulinum Market II-2 Changing Consumer Belief II-3 Under-Treated Diseases Boost Demand for Off- Label Products II-3 Burgeoning Consumer Awareness II-3 'Feeling' to Look Good - Driving Aesthetic Market II-3 Expansion of Financing Services to Propel Growth II-3 Adverse Effects Impedes Market Growth II-3 High Cost - A Major Market Restraint II-4 Concern over Long-Term Side Effects II-4 2. Competitive Landscape II-5 Allergan Dominates Global Botulinum Toxin Market II-5 Table 1: Revenues of Allergan, Inc (2001-2005): Net Sales of Botox(R)/Neuromodulator(In US$ Million) (includes corresponding Graph/Chart) II-5 Botox Dominance Remains Stable in the Global Market II-6 Clinical Trails in Progress for Botox II-6 Ipsen - Major Player in Botulinum Toxin Market II-6 Table 2: Revenues of Ipsen Group (2004 & 2005): Net Sales of Dysport(R) (In _ Million) II-6 Clinical Trails in Progress for Dysport II-7 Solstice - Only Global Manufacturer of Type B Botulinum Toxin II-7 Table 3: Leading Players in Global Botulinum Toxin (Therapeutic) Market (2005): Percentage Breakdown by Revenues for Allergan (Botox(R)), Solstice (Myobloc(R)), Ipsen and (Dysport(R)) (includes corresponding Graph/Chart) II-7 Table 4: Leading Players in Global Botulinum Toxin (Cosmetic) Market (2005): Percentage Breakdown by Revenues for Allergan (Botox(R)), Ipsen (Dysport(R)/Reloxin(R)), and Others (includes corresponding Graph/Chart) II-7 Worldwide Botulinum Toxin Market (2005): Competitors Profile of the Top 2 Companies II-8 Comparison of Allergan's Botox(R) and Ipsen's Reloxin(R) II-8 Table 5: Worldwide Botulinum Toxin Market (2005 & 2006): Percentage Breakup by Key Products - Botox(R), Dysport(R), Myobloc(R), and Others(R) (includes corresponding Graph/Chart) II-9 3. Product Overview II-10 Botulinum Toxin - An Introduction II-10 Chemical Overview II-11 Mechanism of Botulinum Toxin II-11 Side Effects II-11 Immunogenicity Effects Response to Botulinum Therapy II-12 A Peek into the History and Development II-12 Botulinum Toxin - A Classification II-13 Botulinum Toxin Type A II-13 Botox(R) II-13 Historical Timeline of Botox: 1885-2002 II-14 Botox Approvals and Indications in Select Global Regions II-15 Dysport(R) II-15 Xeomin(R) II-15 Botulinum Toxin Type B II-15 Myobloc(R) II-16 Key Products in Botulinum Toxin Type A, Type B II-16 Competitive Overview of Botox(R) - Cosmetic Purpose ( Smoothing of Facial Wrinkles) II-17 Other Types II-17 Applications of Botulinum Toxin II-17 Botulinum - Toxin or Treatment? II-17 Therapeutic Applications of Botulinum Toxin II-18 Botulinum Toxin for Movement Disorders II-18 Botulinum Toxin Cures Dystonia II-18 Botulinum is Beneficial for Cervical Dystonia II-19 Botulinum Toxin Cures Laryngeal Dystonia II-19 Ease from Writer's Cramp II-19 Botulinum - Useful To Treat Oromandibular Dystonia II-20 Tics II-20 Tremors II-20 Parkinson's Disease II-20 Botulinum Toxin Treats Hemifacial Spasm II-20 Is Botulinum Toxin an Answer to Blepharospasm? II-21 Tantalizing Effect in Strabismus II-21 Childhood Strabismus II-21 Botulinum Toxin Helps Spasticity Cure Better II-22 Stroke II-22 Traumatic Brain Injury II-22 Cerebral Palsy II-22 Multiple Sclerosis II-23 Botulinum Toxin Soothes Pain II-23 Botulinum Heals Hypertonic Disorders II-23 Cosmetic Applications of Botulinum Toxin II-24 Botulinum Toxin Irons Out Facial Wrinkles II-24 Botulinum Lessens Facial Scarring II-25 Botulinum Toxin (Botox) Users Becoming Addictive II-25 Key Cosmetic Indications for Botulinum Toxin II-25 Additional Applications II-26 Positive Response of Rigid Spine Syndrome to Botulinum Toxin II-26 Botulinum Toxin Effective in Bladder Dysfunctions II-26 Botox Provides Respite from Tinnitus II-27 Botulinum Toxin for Anal Fissure II-27 Can Botox Prevent Baldness? II-27 Refractory Vaginismus and Botulinum II-27 Botulinum Toxin Helps to Cure Dysphagia II-28 Encouraging Effects of Botox in Migraine II-28 Botulinum Eases Severe Facial Pain II-28 Botulinum Provides Relief from Pelvic Floor Pain II-28 Botox Can Treat Children with Non-Neurogenic, Neurogenic Bladder II-29 Botulinum Toxin Finds Application in Cancer Treatment II-29 Botox Can Reduce Pain, Itching and Hand Eczema II-29 Botulinum Reduces Plantar Fasciitis Pain II-29 Botox Helps to Treat Carpal Tunnel Syndrome II-29 Other Indications for Botulinum Toxin II-30 Terrorist and Military Exploitation of Botulinum Toxin II-30 Botulism - Infection from Botulinum II-30 Types of Botulism II-31 Classical or Food Borne Botulism II-31 Home Canning - Culprit Behind Botulism II-31 Wound Botulism II-32 Infant Botulism II-32 Botulism Outbreak in Animals II-32 Safety Precautions II-33 Medicinal Investigations II-33 Vaccine for Botulinum Toxin II-34 Technological Development II-34 US Inventor Develops New Fermentation Process II-34 4. Recent Industry Activity II-35 Allergan and Clinique Form Strategic Collaboration II-35 Ipsen and Medicis File BLA for Reloxin(R) II-35 Medicis Plans Investment in Revance II-35 Galderma Receives Distribution Rights for Dysport (R) II-35 Allergan to Acquire Espirit Pharma II-35 Allergan Launches "Project: Sweat Free" II-36 Solstice Neurosciences Inks Commercialization Agreement II-36 Ipsen Partners with Galderma II-36 Allergan Rolls Out New Division with Acquisition of Inamed II-36 FTC Mandates Allergan Divest Rights to Reloxin II-36 Medicis Inks Agreement with Ipsen II-36 Solstice Neurosciences Inks Licensing Agreement with DreamPharma II-37 Botox Enters India Market II-37 Mentor Begins Phase-I Clinical Trial on Botulinum Toxin II-37 Allergan Inks Agreement with GlaxoSmithKline II-37 DOR BioPharma Inks Agreement with Dowpharma II-38 Merz Pharma Receives Approval for Botulinum Toxin Type A II-38 Mentor Initiates Phase-I Clinical Trial II-38 Mentor Establishes New Production Facility II-38 DOR BioPharma and Thomas Jefferson University Teams-Up with US Army II-38 Mentor Inks Licensing Agreement with WARF II-39 Solstice Acquires World Rights for Myobloc II-39 Inamed Rolls Out Reloxin Brand II-39 5. Focus on Select Key Players II-40 Allergan, Inc (USA) II-40 Ipsen Group (France) II-40 Metabiologics Inc, (USA) II-40 Merz Pharmaceuticals GmbH (Germany) II-41 Mentor Corporation (USA) II-41 Solstice Neurosciences, Inc. (USA) II-41 6.
Global Market Perspective II-42 Table 6: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region - US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart) II-42 Table 7: World Long-term Projections for Botulinum Toxin by Geographic Region - US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart) II-42 Table 8: World 10-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World for the Years 2003, 2008 & 2012 II-43 Table 9: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region - US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart) II-44 Table 10: World Long-term Projections for Botulinum Toxin in Cosmetic Applications by Geographic Region - US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart) II-44 Table 11: World 10-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World for the Years 2003, 2008 & 2012 II-45 Table 12: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region - US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart) II-46 Table 13: World Long-term Projections for Botulinum Toxin in Therapeutic Applications by Geographic Region - US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart) II-46 Table 14: World 10-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World for the Years 2003, 2008 & 2012 II-47 III. MARKET 1. The United States III-1 A.Market Analysis III-1 Botulinum Toxin Market to Grow at a Healthy Rate III-1 Botox Leads the US Botulinum Toxin Market III-1 Botox Growth - Largely Supported by FDA Approval for Cosmetic Use III-1 Botox Approvals and Indications in the US III-2 Market Dynamics III-2 Booming Non-Surgical Treatments III-2 Aging Baby Boomers Drive Aesthetic Business III-2 Increasing Physician Base Impels Botulinum Market III-2 Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin III-3 Increasing Off-label Use of Botulinum Toxin III-3 Medical Spas - Growing in Number III-3 Heightened Competition Limits Growth III-3 Arduous Regulations Deter Product Progress III-4 Botulism Poisoning - A Major Concern III-4 Botox Injection - Popular Non-Invasive Cosmetic Procedure III-4 Table 15: Number of Botox Injections (2000-2005) (includes corresponding Graph/Chart) III-5 Table 16: Botox Injections by Gender (2004) III-5 Table 17: Botox Injections by Age Group (2004) (includes corresponding Graph/Chart) III-5 Botox Attracts American Men III-6 Table 18: Non-Invasive Cosmetic Procedures in the US (2005): Percentage of Patients Treated by All US-Based AACS Members Practices (includes corresponding Graph/Chart) III-6 Table 19: Cosmetic Procedures (Surgical/Non-Surgical) in the US (2005): Percentage of Patients Treated by All US-Based AACS Members Practices III-6 Factors to be Considered Prior to Cosmetic Botox Treatment III-7 Botox for Spasticity - Improved Quality of Life III-7 Coding and Reimbursement III-7 US Cosmetic Market - Statistical Data III-8 Table 20: Cosmetic Market in the US (2004 & 2005): Leading Surgical Procedures (includes corresponding Graph/Chart) III-8 Table 21: Cosmetic Market in the US (2004 & 2005): Leading Non-Surgical Procedures (includes corresponding Graph/ Chart) III-9 Table 22: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Gender III-9 Table 23: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Age Group (includes corresponding Graph/Chart) III-9 Table 24: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Facility (includes corresponding Graph/Chart) III-10 Table 25: Cosmetic Market in the US (2004): Percentage Breakdown by Procedure Type III-10 Technological Development III-10 Strategic Corporate Developments III-10 Key Players III-14 B.Market Analytics III-16 Table 26: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart) III-16 Table 27: US Long-term Projections for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart) III-16 Table 28: US 10-Year Perspective for Botulinum Toxin - Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications for the Years 2003, 2008 & 2012 III-17 2. Rest of World III-18 A.Market Analysis III-18 Current and Future Analysis III-18 Europe III-18 Botox Demand Increases with Zeal For Beauty III-18 Botox Approvals and Indications in Select European Countries III-18 Botox to Support Radiation Treatments III-19 Asia III-19 India - An Emerging Market for Botox III-19 Korea - Fast Catching Up the Trend III-19 Australia - A Well Supported Market III-19 Botox Approvals and Indications in Select Asian Countries III-20 Botox Approvals and Indications in Select Latin American Regions III-20 Botox Approvals and Indications in Other Select Global Regions III-21 Strategic Corporate Developments III-21 Key Players III-22 B.Market Analytics III-23 Table 29: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart) III-23 Table 30: Rest of World Long-term Projections for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart) III-24 Table 31: Rest of World 10-Year Perspective for Botulinum Toxin - Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications for the Years 2003, 2008 & 2012 III-24 IV. COMPETITIVE LANDSCAPE.
